OB/GYN and Women's Health

Guest: Sara Horst, MD, MPH, FACG While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it’s still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.

Host: Claire Gill Guest: Andrea Singer, MD, FACP, CCD Menopause accelerates bone loss due to declining estrogen levels, increasing the risk of osteoporosis and fractures. To learn how we can best support bone health during this transition, CEO of the Bone Health and Osteoporosis Foundation Claire Gill speaks with Dr. Andrea Singer, Chief Medical Officer of the Bone Health and Osteoporosis Foundation, Professor of Medicine and Obstetrics and Gynecology at MedStar Georgetown University Hospital, and a member of the National Menopause Foundation's Medical Advisory Committee.

Host: Brian Slomovitz, MD Guest: Robert L. Coleman, MD, FACOG, FACS In recent years, the treatment landscape for recurrent or metastatic cervical cancer has undergone significant shifts with FDA approvals of first-line pembrolizumab plus platinum-doublet with or without bevacizumab and second-line tisotumab vedotin. The introduction of frontline immune checkpoint blockade also added to the challenges faced by clinicians as they choose optimal regimens for their patients. In this online CME activity, Dr. Coleman and Dr. Slomovitz offer strategies for treatment selection and sequencing with immune checkpoint inhibitors and antibody-drug conjugates for relapsed cervical cancer. Tune in to hear their expert perspectives on biomarker testing, clinical trial evidence, and multidisciplinary management of adverse events associated with these therapies to make sure your patients are getting the most out of these advances.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO While endocrine therapy (ET) and CDK4/6 inhibitors are the standard for treating ER+/HER2- metastatic breast cancer, patients can become resistant to ET. To overcome these resistance mechanisms, the ELEVATE study examines whether combining elacestrant with ET could help address this unmet need. Here to share the preliminary findings from ELEVATE with Dr. Charles Turck is lead study investigator Dr. Hope Rugo. She’s also the Winterhof Distinguished Professor of Breast Oncology and the Director of Breast Oncology and Clinical Trials Education at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center.

Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there’s uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy, contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.

Unknown: Arnold Advincula, MD With over 20 years of experience performing the transabdominal cerclage, Dr. Arnold Advincula, Chief of Gynecologic Specialty Surgery at NewYork-Presbyterian and Columbia, has a deep expertise in helping women with cervical insufficiency achieve successful pregnancies. Through the expanded use of robotics, Dr. Advincula and his team are completing the procedure minimally invasively and with more accuracy and precision. Watch to learn how this advanced technique is transforming gynecologic surgery by reducing recovery time and helping women reach their reproductive goals. © 2024 NewYork-Presbyterian

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erika Hamilton, MD The ELECTRA trial is seeking to evaluate the combination of elacestrant with abemaciclib in patients with ER+/HER2- metastatic breast cancer regardless of metastatic site and ESR1 status to see if this could be an all-oral treatment option before using fulvestrant-based combinations or chemotherapy-based regimens. And now, the preliminary results are here. Joining Dr. Charles Turck to share what we’ve learned so far from the ELECTRA trial is study investigator Dr. Erika Hamilton.

Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Since postpartum depression is a serious medical condition that can negatively impact mothers, infants, and partners, it is important to identify symptoms in a timely manner. Dr. Jennifer Payne and Dr. Melissa Simon are here to share their clinical experiences screening patients for postpartum depression, explore strategies to overcome common challenges in screening, and identify best practices for collaborating in the care of perinatal women. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References Diagnostic and Statistical Manual of Mental Disorders: DSM-5™Dev PsycholCurr Med Res Opin Ment Health Fam Med Sage Therapeutics and the Sage Therapeutics logo …

Host: Matt Birnholz, MD Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Postpartum depression is a serious medical condition that is among the most common complications during and after pregnancy; however, it is often underdiagnosed. To learn more about screening patients for postpartum depression, Dr. Matt Birnholz speaks with Dr. Jennifer Payne and Dr. Melissa Simon about screening strategies, the impact of health inequities, and the latest medical guidelines regarding the importance of early screening for postpartum depression. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References Diagnostic and Statistical Manual of Mental Disorders: DSM-5™MMWR Morb Mortal Wkly RepJ Clin PsychiatryMent Health Fam Med

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Guest: Sawsan As-Sanie, MD GnRH antagonists have emerged as a viable first-line (or subsequent-line) medical therapy for the management of endometriosis. They have proven to be effective and safe, and their use avoids the flare response observed with GnRH agonists. Join Drs. Lee Shulman, Ayman Al-Hendy, and Sawsan As-Sanie as they discuss the estrogen threshold hypothesis from the perspective of GnRH antagonists and delve into clinical data supporting the use of GnRH antagonists in the medical management of endometriosis.

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Linda Bradley, MD Guest: Melissa Simon, MD The use of validated patient questionnaires, notably the SF-36 and EHP-30 scales, can greatly hasten the suspicion for an endometriosis diagnosis. Coupled with shared decision-making, or SDM, this patient-centered process can help ensure therapeutic adherence. Join Drs. Lee Shulman, Melissa Simon, and Linda Bradley as they discuss how to utilize the SF-36 and EHP-30 questionnaires in clinical practice and explore strategies to facilitate patient-healthcare provider discussions to improve overall short- and long-term patient outcomes.

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Linda Bradley, MD Guest: Melissa Simon, MD Both provider- and patient-related healthcare disparities exist in the diagnosis and management of endometriosis. Many disparities derive from incorrect historical biases, while others are associated with social determinants of health, or SDOH. Join Drs. Lee Shulman, Linda Bradley, and Melissa Simon as they address these issues to help facilitate a patient-centered practice environment for all patients.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Leigh Anne Cantrell, MD, MSPH The updated ASCCP guidelines now address the use of dual-stain technology for cervical cancer management. CINtec PLUS Cytology is a test for the co-expression of p16 and Ki67 and confirms the presence of a transforming HPV infection and defines patients with high-risk cervical disease. To learn more about these guidelines and how to apply them in practice, join Dr. Leigh Cantrell, Medical Physician and Fellow in the American College of Obstetrics and Gynecology. COBAS and CINTEC are trademarks of Roche. All other product names and trademarks are the property of their respective owners. 07/24

Host: Ashley Baker, MSN, PMHNP Guest: Kathleen Nadeau, PhD Girls and women with ADHD are often underdiagnosed and undertreated compared to boys and men, which puts them at risk of serious issues like unplanned pregnancies, cigarette smoking, and even anxiety and depression. To help us better identify and manage girls and women with ADHD, psychiatric nurse practitioner Ashley Baker speaks with Dr. Kathleen Nadeau, Founder and Clinical Director of the Chesapeake Center for ADHD Learning and Behavioral Health in Bethesda, Maryland.

Guest: Kathleen Nadeau, PhD It’s important to be aware of the different ways ADHD impacts girls and women compared to boys and men, which is why Dr. Kathleen Nadeau is here to help shed light on those differences. Dr. Nadeau is the Founder and Clinical Director of the Chesapeake Center for ADHD Learning and Behavioral Health in Bethesda, Maryland.

Host: Warner K. Huh, MD Guest: Kimberly Levinson, MD, MPH More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.

Host: Jennifer Caudle, DO Guest: Tamera A. Paczos, MD, FACOG, FACP The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories. COBAS and CINTEC are trademarks of Roche. All other product names and trademarks are the property of their respective owners. 02/23

Host: Michael Lewiecki, MD, FACP, FACE Although step therapy is the approach that many health plans and organizations are fond of, individualizing treatment decisions for patients with osteoporosis is essential, especially those who are at risk of fractures. To learn how you can create personalized treatment plans for patients with osteoporosis, tune in to hear Dr. Michael Lewiecki give us a recap of the session he presented at the 2024 Congress of Clinical Rheumatology.

Host: Michael Lewiecki, MD, FACP, FACE Here to talk about current concepts in the management of osteoporosis like insurance coverage, therapy sequencing, and comparative effectiveness is Dr. Michael Lewiecki, who presented a session on this exact topic at the 2024 Congress of Clinical Rheumatology.

Host: Eliza C. Miller, MD Stroke is one of the leading causes of death in pregnancy in the United States, underscoring the importance of knowing the causes, risks, and treatment of stroke in pregnancy and postpartum. That’s why Dr. Eliza Miller is here to share key insights from her session at the 2024 AAN Annual Meeting that focused on this exact topic. Dr. Miller is an Associate Professor of Neurology in the Division of Stroke and Cerebrovascular Disease at Columbia University.